SCHEMBL753408

SCHEMBL753408

Cc1n[c]cc(Nc2cnccn2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
ADORA2A P29274 1/20 0.34
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
PIK3CA P42336 2/20 0.34
MAPK1 P28482 1/20 0.34
MAPK8 P45983 1/20 0.34
MAPK9 P45984 1/20 0.34
MAPK10 P53779 1/20 0.34
MTOR P42345 1/20 0.34
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33
CDK5 Q00535 1/20 0.33
DYRK1A Q13627 1/20 0.33
CDK5R1 Q15078 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750473 0.77 KMT2A (0.46) KDM4EALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL751265 0.76 GSK3A (0.40) CCNA2CDK2CCNA1CDK5KDR
SCHEMBL753307 0.75 KMT2A (0.41) KDM4EALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL750710 0.75 TRPV4 (0.43) MAPK10KDR
SCHEMBL22970856 0.75 PIK3C3 (0.47) KDM4EALDH1A1HPGDKARS1
SCHEMBL5787755 0.74 KDR (0.47) KDM4EALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL22971366 0.70 ALDH1A1 (0.41) KDM4EALDH1A1HPGDSMN1; SMN2ADORA2A
SCHEMBL753277 0.70 GOT1 (0.41) PIK3CAMTORBTKLCK
SCHEMBL22970846 0.69 MAPK1 (0.42) KDM4EALDH1A1HPGDSMN1; SMN2ADORA2A
SCHEMBL22971351 0.68 ALDH1A1 (0.42) KDM4EALDH1A1HPGDSMN1; SMN2ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD KDM4E 1665/4885ALDH1A1 4785/4885HPGD 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.